Centrophenoxine

DMAE Pro-drug with a Built-in BBB Shuttle#

Centrophenoxine is the ester of DMAE (dimethylaminoethanol) and pCPA (para-chlorophenoxyacetic acid). The pCPA half is not pharmacologically inert decoration — it is a lipophilic carrier that drags DMAE across the blood-brain barrier far more efficiently than free DMAE administration. After absorption, hepatic and plasma esterases cleave the ester rapidly (parent compound t½ measured in minutes), releasing the active DMAE moiety centrally and the pCPA metabolite peripherally. This is why the literature consistently quantifies pCPA rather than the parent — the parent has effectively done its job by the time it reaches systemic circulation.

The practical consequence for users: centrophenoxine delivers a more substantial central cholinergic signal per milligram of DMAE than DMAE bitartrate or DMAE-containing nutraceuticals, which is why it sits in the "racetam cofactor" tier alongside alpha-GPC and CDP-choline rather than in the generic-supplement tier.

Cholinergic Upregulation via SAMe-Dependent Methylation#

DMAE is structurally choline minus one methyl group. Once central, it is methylated through SAMe-dependent transfer into choline, expanding the pool available for acetylcholine synthesis in cortical and hippocampal neurons. In aged rodents, centrophenoxine roughly doubles the choline- and ACh-elevating potency of an equimolar DMAE dose — the BBB-penetration advantage compounds with substrate efficiency.

This is the mechanism that drives the subjective "fog-clearing" and memory-consolidation effects experienced users report, and it is also why pairing with a methyl donor (TMG 1–2 g/day or a methylated B-complex) is part of the standard longer-block protocol — the conversion is methyl-hungry, and methyl status is the rate-limiter on chronic administration.

Lipofuscin Clearance and Membrane Repair#

The mechanism that distinguishes centrophenoxine from every other choline source is its action on lipofuscin — the oxidatively cross-linked lipid/protein "age pigment" that accumulates in neurons, retinal pigment epithelium, myocardium, and skin with age. Nandy's classic guinea-pig work demonstrated microglia-mediated lipofuscin clearance at 30 mg/kg/day:

"Centrophenoxine administration produced a highly significant decrease in the number of lipofuscin granules...reduction continued for a further 2 months after withdrawal." — Nandy K., Experimental Gerontology (1983)

The post-withdrawal persistence is mechanistically important — it implies the drug initiates a clearance process that runs autonomously once started, which is the published rationale for the 8 weeks on / 8–12 weeks off block structure rather than continuous administration. This is also the binding logic behind centrophenoxine's place in longevity stacks (spermidine, NMN/NR, astaxanthin) and the basis of the more speculative aesthetic / "age-spot" use case.

Antioxidant Activity and Membrane Stabilization#

DMAE scavenges hydroxyl radicals directly and is incorporated into phosphatidylcholine, the dominant phospholipid of neuronal membranes. The downstream effect is reduced lipid peroxidation and restored membrane fluidity — the central tenet of Zs-Nagy's "membrane hypothesis of aging" that underpins most of the longevity rationale. In a rotenone-induced Parkinson's model:

"Centrophenoxine supplementation significantly restored antioxidant status and reduced the formation of lipid peroxides in the brains of rats treated with rotenone." — Verma R, Nehru B., Neurochemistry International (2009)

For physique-focused users, the relevant translation is post-cycle neuroprotection — heavy oral AAS cycles, long trenbolone runs, and aggressive stimulant use all elevate central oxidative load, and the membrane-repair mechanism is the same one being targeted.

Pharmacokinetics That Shape the Protocol#

The kinetics dictate dosing structure more rigidly than most nootropics:

"The Tmax of the major metabolite (pCPA) was 1.25 ± 0.53 hours, and the t1/2 was around 2–4 hours, supporting a BID to TID dosing schedule for oral formulations." — Wang Y, et al., Clinical Therapeutics (2008)

The combination of short metabolite half-life and reliable evening insomnia is why the modal community protocol is 250–500 mg at breakfast + 250–500 mg at lunch, with the lipofuscin-clearance block (1,000–1,500 mg/day) split across breakfast, mid-morning, and lunch rather than pushed into the afternoon.

Outcome Summary#

Each mechanism maps cleanly to a community use case:

• Cholinergic upregulation → racetam cofactor, daily fog-clearing, post-cycle cognitive rescue
• Lipofuscin clearance → 8-week longevity blocks; experimental aesthetic / age-pigment protocol
• Antioxidant / membrane stabilization → post-AAS neurorecovery, paired with NAD+ precursors and astaxanthin
• Pro-drug PK → why centrophenoxine outperforms equimolar DMAE for users who didn't respond to bitartrate or to alpha-GPC

The cognitive payoff is consolidation-weighted, not stimulant-like — subjects expecting a noopept- or modafinil-style acute hit are routinely disappointed at week one. The compound rewards block-structured, methyl-supported administration over chronic daily use.

Common (most users)#

• Headache / jaw or neck tension — the classic DMAE signature. Usually resolves by lowering the per-dose to 250 mg and splitting BID, or by adding a methyl donor (TMG 1–2 g, or a methylated B-complex) to support SAMe-dependent conversion of DMAE to choline.
• Mild GI upset — administration with food (breakfast and lunch) resolves it in nearly all cases.
• Insomnia / sleep-onset disruption — reliably triggered by dosing after ~2 p.m. The fix is mechanical: keep all doses in the first half of the day. Final dose no later than lunch.
• Irritability / mild over-stimulation — most common in the first week and at doses above 750 mg/day in stimulant-sensitive users. Back off to 250 mg BID for 1–2 weeks before titrating up.
• Flat / "wired but tired" affect — a sign of cholinergic overshoot, often from stacking with alpha-GPC or CDP-choline on top of centrophenoxine. Drop the additional choline source; centrophenoxine is itself the choline cofactor in any racetam stack.

Uncommon (dose-dependent or individual)#

• Mild blood pressure elevation — documented above ~1 g/day in susceptible subjects. Recomp- or cycle-focused users already managing on-cycle hypertension should monitor cuff readings during the first 2 weeks and cap dosing at 500–750 mg/day if systolic creeps.
• Depressive flattening / anhedonia — paradoxical but reported, almost always above 1.5 g/day and almost always reversible within a week of dose reduction.
• Muscle twitching / fasciculations — cholinergic over-supply. Back off dose and re-evaluate other choline sources in the stack.
• Brain fog at high doses — counterintuitive but consistent with the "more is worse" pattern above the 1 g/day mark. The dose-response curve plateaus; pushing past it produces inverted returns.
• LFT considerations on year-plus continuous protocols — centrophenoxine is hepatically hydrolyzed. Long uninterrupted runs warrant a standard liver panel; the 6–8 week on / 2–4 week off cycle pattern sidesteps this entirely.

Rare but serious#

• Hyperexcitability / agitation — described in elderly dementia subjects in the older European literature, rare in neurologically intact users. Warning signs are restlessness, racing thoughts, and unrelenting insomnia despite morning-only dosing. Discontinue.
• Lowered seizure threshold — cholinergic load is the mechanism. Any new-onset twitching that progresses beyond simple fasciculations, or any aura-type symptoms, is a hard stop.
• Worsening of pre-existing dyskinesia in advanced parkinsonian states.
• Paradoxical confusion in subjects with significant baseline cognitive impairment — not relevant to the typical biomogging reader but documented in the dementia trials.

Hard contraindications#

• Pregnancy and women of childbearing potential planning conception. DMAE has shown teratogenic signals in animal models — neural-tube-type defects. This line is not crossed.

"DMAE, the active moiety of centrophenoxine, has demonstrated teratogenicity in animal models; use is contraindicated in pregnancy or planned conception." — Alzheimer's Drug Discovery Foundation, Cognitive Vitality Report (2020)

• Seizure disorders / epilepsy. Cholinergic upregulation lowers seizure threshold.
• Severe parkinsonism with established dyskinesia. Worsens involuntary movement.
• Concurrent strong anticholinergics (scopolamine, high-dose diphenhydramine, certain TCAs). The pharmacology cancels and cognitive output becomes unpredictable.
• Evening dosing. Not a safety event, but a protocol-level non-negotiable — sleep architecture loses every time.

Sex-specific and post-cycle notes#

Centrophenoxine is non-hormonal: no androgen receptor activity, no estrogenic or progestogenic signal, no HPTA involvement, no PCT requirement. It stacks cleanly into post-AAS neuro-recovery protocols (500–750 mg/day for 6–8 weeks) alongside tongkat ali, low-dose tadalafil, and a sleep peptide, and does not interfere with SERM-based PCT.

For women, the compound is otherwise well-tolerated at the same dose ranges as men — there is no sex-specific dose scaling — but the pregnancy / planned-conception contraindication above is absolute and forecloses use in that window entirely. Hormonal birth control is not affected.